decision-making process is vital. To that end, health care economists and patients need to be involved as these pathways are being formulated. Second, understanding various value-based utility differences from a patient perspective suggests that a formula looking beyond efficacy and toxicity is urgently needed. To properly design and refine this formula, clinical trials have to incorporate patients' reported outcomes and should be designed to study and report subsequent therapies following study drug discontinuation beyond a censoring event [21] . Third, consideration for "real-world" registries is needed to better understand patterns of care and encountered toxicities that could vary from reported trial data. Lastly, updating these pathways is critical for sustainability and for evaluating whether this strategy truly and positively impact the delivery of care and the overall costs. Pathways have the potential to improve the quality and cost of care, decrease variance, increase clinical trial accrual, and optimize patients' outcomes, but only if they are designed and maintained with scientific rigor that incorporates the needs of all stakeholders. 
